Article ; Online: Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
2021 Volume 41, Issue 2, Page(s) 37–43
Abstract: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been a major threat to global public health. In Indonesia, the cases have rapidly increased, and the case fatality rate remains high. ... ...
| Abstract | Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been a major threat to global public health. In Indonesia, the cases have rapidly increased, and the case fatality rate remains high. With COVID-19, most of the deaths have been caused by acute respiratory distress syndrome and dysregulation of the immune response. A lung biopsy from a patient with COVID-19 showed inflammatory cellular infiltration with diffuse alveolar damage. Massive pulmonary destruction has also been reported as a result of highly increased levels of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-1β, interferon-γ (IFN-γ), induced protein 10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1). IL-6 is an inflammatory cytokine produced by various cell types, including immune cells and nonleukocytes, such as endothelial cells, fibroblasts, epithelial cells, type II pneumocytes, and certain tumor cells. Several studies have shown that IL-6 contributes to the severity and mortality of COVID-19. In this review, we would like to explore the immune response in COVID-19 and the role of IL-6 in the immunopathogenesis of COVID-19. |
|---|---|
| MeSH term(s) | Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/drug therapy ; COVID-19/pathology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/pathology ; Cytokine Release Syndrome/prevention & control ; Humans ; Indonesia ; Interleukin-6/immunology ; Janus Kinase 1/antagonists & inhibitors ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase Inhibitors/therapeutic use ; Pyrazoles/therapeutic use ; Receptors, Interleukin-6/antagonists & inhibitors ; Respiratory Distress Syndrome/drug therapy ; SARS-CoV-2/drug effects ; SARS-CoV-2/immunology ; Signal Transduction/immunology |
| Chemical Substances | Antibodies, Monoclonal, Humanized ; IL6 protein, human ; Interleukin-6 ; Janus Kinase Inhibitors ; Pyrazoles ; Receptors, Interleukin-6 ; ruxolitinib (82S8X8XX8H) ; JAK1 protein, human (EC 2.7.10.2) ; JAK2 protein, human (EC 2.7.10.2) ; Janus Kinase 1 (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2) ; tocilizumab (I031V2H011) ; sarilumab (NU90V55F8I) |
| Language | English |
| Publishing date | 2021-03-10 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
| ZDB-ID | 1226675-9 |
| ISSN | 1557-7465 ; 1079-9907 |
| ISSN (online) | 1557-7465 |
| ISSN | 1079-9907 |
| DOI | 10.1089/jir.2020.0135 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1748: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.